| Age (yr) | 5.9 (range: 1-15) |
| Sex (M/F) | 20/10 |
| Underlying disease | |
| Severe aplastic anemia | 5 |
| Acute lymphoblastic leukemia | 8 |
| Acute myelogenous leukemia | 8 |
| Chronic myelocytic leukemia | 3 |
| Neuroblastoma | 2 |
| Myelodysplastic syndrome | 1 |
| Malignant lymphoma | 2 |
| Adrenoleukodystrophy | 1 |
| Donor | |
| HLA-matched sibling | 22 |
| HLA-mismatched related donor | 3 |
| HLA-matched unrelated donor | 5 |
| GVHD prophylaxis | |
| MTX | 12 |
| MTX + CyA | 18 |
| Conditioning regimen | |
| TBI + L-PAM + others | 13 |
| TBI + CY + others | 5 |
| BU + L-PAM | 7 |
| Others | 5 |
| Age (yr) | 5.9 (range: 1-15) |
| Sex (M/F) | 20/10 |
| Underlying disease | |
| Severe aplastic anemia | 5 |
| Acute lymphoblastic leukemia | 8 |
| Acute myelogenous leukemia | 8 |
| Chronic myelocytic leukemia | 3 |
| Neuroblastoma | 2 |
| Myelodysplastic syndrome | 1 |
| Malignant lymphoma | 2 |
| Adrenoleukodystrophy | 1 |
| Donor | |
| HLA-matched sibling | 22 |
| HLA-mismatched related donor | 3 |
| HLA-matched unrelated donor | 5 |
| GVHD prophylaxis | |
| MTX | 12 |
| MTX + CyA | 18 |
| Conditioning regimen | |
| TBI + L-PAM + others | 13 |
| TBI + CY + others | 5 |
| BU + L-PAM | 7 |
| Others | 5 |
Abbreviations: MTX, methotrexate; CyA, cyclosporin A; TBI, total body irradiation; L-PAM, melphalan; CY, cyclophosphamide; BU, busulfan.